400 related articles for article (PubMed ID: 29511897)
1. Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis).
Gonzalez-Duarte A
Clin Auton Res; 2019 Apr; 29(2):245-251. PubMed ID: 29511897
[TBL] [Abstract][Full Text] [Related]
2. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
Conceição I
Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774
[TBL] [Abstract][Full Text] [Related]
3. Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy.
Gendre T; Planté-Bordeneuve V
Clin Auton Res; 2019 Sep; 29(Suppl 1):25-31. PubMed ID: 31506870
[TBL] [Abstract][Full Text] [Related]
4. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
González-Duarte A; Berk JL; Quan D; Mauermann ML; Schmidt HH; Polydefkis M; Waddington-Cruz M; Ueda M; Conceição IM; Kristen AV; Coelho T; Cauquil CA; Tard C; Merkel M; Aldinc E; Chen J; Sweetser MT; Wang JJ; Adams D
J Neurol; 2020 Mar; 267(3):703-712. PubMed ID: 31728713
[TBL] [Abstract][Full Text] [Related]
5. 6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR).
Vita GL; Stancanelli C; Gentile L; Barcellona C; Russo M; Di Bella G; Vita G; Mazzeo A
Neuromuscul Disord; 2019 Mar; 29(3):213-220. PubMed ID: 30718023
[TBL] [Abstract][Full Text] [Related]
6. Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review.
Cruz MW
Clin Auton Res; 2019 Sep; 29(Suppl 1):19-24. PubMed ID: 31407119
[TBL] [Abstract][Full Text] [Related]
7. Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7.
Dyck PJB; González-Duarte A; Obici L; Polydefkis M; Wiesman JF; Antonino I; Litchy WJ; Dyck PJ
J Neurol Sci; 2019 Oct; 405():116424. PubMed ID: 31445300
[TBL] [Abstract][Full Text] [Related]
8. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
[TBL] [Abstract][Full Text] [Related]
9. Burden of hereditary transthyretin amyloidosis on quality of life.
Yarlas A; Gertz MA; Dasgupta NR; Obici L; Pollock M; Ackermann EJ; Lovley A; Kessler AS; Patel PA; White MK; Guthrie SD
Muscle Nerve; 2019 Aug; 60(2):169-175. PubMed ID: 31093980
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review.
Gonzalez-Duarte A; Valdés-Ferrer SI; Cantú-Brito C
Clin Auton Res; 2019 Sep; 29(Suppl 1):1-9. PubMed ID: 31473866
[TBL] [Abstract][Full Text] [Related]
11. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
Nie T; Heo YA; Shirley M
Drugs; 2023 Oct; 83(15):1425-1432. PubMed ID: 37728865
[TBL] [Abstract][Full Text] [Related]
12. Familial Oculo-Leptomeningeal Transthyretin Amyloidosis Caused by Leu55Arg Mutation.
Kleefeld F; Knebel F; Eurich D; Schatka I; Blüthner E; Schönfeld S; Amthauer H; Hahn K
J Neuromuscul Dis; 2020; 7(4):515-519. PubMed ID: 32741838
[TBL] [Abstract][Full Text] [Related]
13. Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients.
Conceição I; Miranda B; Castro J; de Carvalho M
Eur J Neurol; 2018 Nov; 25(11):1320-e115. PubMed ID: 29924456
[TBL] [Abstract][Full Text] [Related]
14. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Planté-Bordeneuve V; Lin H; Gollob J; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
Expert Opin Pharmacother; 2019 Mar; 20(4):473-481. PubMed ID: 30489166
[TBL] [Abstract][Full Text] [Related]
15. Neuropathy Associated with Systemic Amyloidosis.
Kaku M; Berk JL
Semin Neurol; 2019 Oct; 39(5):578-588. PubMed ID: 31639841
[TBL] [Abstract][Full Text] [Related]
16. Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches.
Serrano D; Atzinger CB; Botteman MF
Neurol Ther; 2018 Jun; 7(1):141-154. PubMed ID: 29611130
[TBL] [Abstract][Full Text] [Related]
17. Blood pressure and orthostatic hypotension as measures of autonomic dysfunction in patients from the transthyretin amyloidosis outcomes survey (THAOS).
González-Duarte A; Barroso F; Mundayat R; Shapiro B
Auton Neurosci; 2019 Dec; 222():102590. PubMed ID: 31726319
[TBL] [Abstract][Full Text] [Related]
18. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis.
Dyck PJB; Coelho T; Waddington Cruz M; Brannagan TH; Khella S; Karam C; Berk JL; Polydefkis MJ; Kincaid JC; Wiesman JF; Litchy WJ; Mauermann ML; Ackermann EJ; Baker BF; Jung SW; Guthrie S; Pollock M; Dyck PJ
Muscle Nerve; 2020 Oct; 62(4):509-515. PubMed ID: 32654156
[TBL] [Abstract][Full Text] [Related]
19. Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort.
Pasutharnchat N; Taychargumpoo C; Vorasettakarnkij Y; Amornvit J
BMC Neurol; 2021 May; 21(1):206. PubMed ID: 34022837
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
